TQB-3002 / Sino Biopharm - LARVOL DELTA

TQB3002: A potent fourth-generation small molecule EGFR-TKI (AACR 2025) - P1 | "The anti-tumor activities of TQB3002 were studied in animal models, including five CDX models of PC9(EGFRd746-750), 32D(EGFRd746-750/T790M), NCI-H1975(EGFR L858R /T790M) and triple mutations PC9(EGFRd746-750/T790M/C797S) and 32D (EGFRL858R/T790M/C797S), as well as in two Osimertinib-resistant PDX models. TQB3002 potently inhibited the kinase activities of EGFR single and double mutations, with IC50 of 0.01 - 0.12 nM, which was 4 - 12 times better than that of Osimertinib. With a clearly differentiated chemical structure, TQB3002 has shown strong activities both in-vitro and in-vivo against EGFR single/double/triple mutants, and is much more effective against the C797S mutation resistant to third-generation EGFR-TKIs. In addition, TQB3002 has good druggability and supports clinical oral QD dosing. It has good selectivity in EGFR single/double/triple mutant cells (36.5-fold selectivity over WT), and low risk of DDI and in-vitro cardiotoxicity are also observed in..."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Clinical Trial of TQB3002 in Patients With Advanced Cancers (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology

Two new drugs from China Biopharmaceuticals were approved for clinical trials for the first time, addressing the problem of drug resistance in malignant tumors [Google translation] (Sino Biopharm Press Release) - "Recently, two Class 1 new drugs of Sino Biopharmaceutical's subsidiary, TQB2029 for injection and TQB3002 tablets, were approved for clinical trials for the first time. They are intended to be used for the treatment of advanced malignant tumors and multiple myeloma, respectively, aiming to improve the drug resistance problem faced by current anticancer drugs."

New trial • Hematological Malignancies • Multiple Myeloma • Oncology • Solid Tumor

Clinical Trial of TQB3002 in Patients With Advanced Cancers (clinicaltrials.gov) - P1 | N=120 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Metastases • New P1 trial • Oncology